Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 4/20 | 0.39 |
| ▸ | SYK | P43405 | 5/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.37 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.35 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3374495 | 0.94 | IDH1 (0.39) | IDH1SYKMAPK3DAPK1TYRO3 | |
| SCHEMBL3375491 | 0.94 | SYK (0.41) | SYKMAPK3DAPK1TYRO3MERTK | |
| SCHEMBL3449532 | 0.93 | SYK (0.45) | IDH1SYK | |
| SCHEMBL3449039 | 0.92 | IDH1 (0.39) | IDH1SYKCNR2MAPT | |
| SCHEMBL3451469 | 0.91 | CNR2 (0.43) | IDH1SYKCNR2 | |
| SCHEMBL3376264 | 0.90 | SYK (0.46) | SYK | |
| SCHEMBL3448415 | 0.90 | SYK (0.39) | IDH1SYKMAPK3DAPK1TYRO3 | |
| SCHEMBL3448433 | 0.89 | SYK (0.39) | SYKMAPK3TYRO3MERTKCNR2 | |
| SCHEMBL3449178 | 0.88 | SYK (0.43) | IDH1SYKMAPK3TYRO3MERTK | |
| SCHEMBL3376690 | 0.88 | TYRO3 (0.40) | SYKMAPK3DAPK1TYRO3MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | IDH1 718/4885SYK 804/4885MAPK3 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.